Serotonin Reuptake Inhibitors in Obstructive Sleep Apnea: Associations in People with and without Epilepsy

Table 2

PWO and PWE: significantly different baseline characteristics.

	PWO (N=68); N (%)	PWE (N=57); N (%)	χ2	p
Gender (male)	37 (54)	33 (58)	0.153	0.696
Hypertension	26 (38)	13 (23)	3.438	0.064
Diabetes	19 (28)	7 (12)	4.616	0.032
Congestive Heart Failure	8 (12)	2 (3.51)	2.872	0.090
Stroke/TIA	15 (22)	8 (14)	1.330	0.249
COPD/asthma	20 (29)	6 (10.5)	6.713	0.010
Tobacco	4 (5.88)	0 (0)	3.464	0.063
Alcohol	0 (0)	0 (0)	------	------
Drug Abuse	2 (2.94)	2 (3.51)	0.032	0.857
Opioids	4 (5.88)	0 (0)	3.464	0.063
Benzodiazepines	18 (26.47)	12 (21)	0.499	0.480
Non-benzodiazepines	9 (13.24)	4 (7.02)	1.286	0.257
AED	18 (26.47)	55 (96.49)	65.712	0.001
	Mean ± SD	Mean ± SD	CI	P
Age (years)	63.21±12.67	54.97±12.65	3.74-12.74	0.001
Body Mass Index	31.54±6.48	30.12±5.39	-0.68-3.52	0.301

SRI: serotonin reuptake inhibitor, TIA: transient ischemic attack, COPD: chronic obstructive pulmonary disease, and AED: antiepileptic drug; : p<0.05.